Who are CAIV-T and TIV's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): H5N1 vaccine (Arepanrix), High-Dose Influenza Vaccine, inactivated split-virus influenza vaccine, Intranasal Influenza Live Attenuated Vaccine, SP Shz TIV, Vaxigrip®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/caiv-t-and-tiv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CAIV-T and TIV — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CAIV-T and TIV (CAIV-T and TIV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Influenza vaccine. Area: Immunology / Infectious Disease.

phase 3 Influenza vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

CAIV-T and TIV (CAIV-T and TIV) — MedImmune LLC. CAIV-T is a live attenuated influenza vaccine administered intranasally, while TIV is a trivalent inactivated influenza vaccine, both designed to induce immune responses against seasonal influenza strains.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
CAIV-T and TIV TARGET	CAIV-T and TIV	MedImmune LLC	phase 3	Influenza vaccine
H5N1 vaccine (Arepanrix)	H5N1 vaccine (Arepanrix)	Canadian Immunization Research Network	marketed	inactivated split-virion influenza vaccine with adjuvant
High-Dose Influenza Vaccine	High-Dose Influenza Vaccine	Saad Jamshed MD	marketed	Inactivated influenza vaccine
inactivated split-virus influenza vaccine	inactivated split-virus influenza vaccine	The Cleveland Clinic	marketed	inactivated influenza vaccine
Intranasal Influenza Live Attenuated Vaccine	Intranasal Influenza Live Attenuated Vaccine	Jiangsu Province Centers for Disease Control and Prevention	marketed	Live attenuated influenza vaccine
SP Shz TIV	SP Shz TIV	Sanofi	marketed	Inactivated influenza vaccine
Vaxigrip®	Vaxigrip®	National University Hospital, Singapore	marketed	Inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Influenza vaccine class)

GlaxoSmithKline · 8 drugs in this class
Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
Seqirus · 2 drugs in this class
MedImmune LLC · 1 drug in this class
AstraZeneca · 1 drug in this class
Novartis · 1 drug in this class
Protein Sciences Corporation · 1 drug in this class
ModernaTX, Inc. · 1 drug in this class
Institute of Vaccines and Medical Biologicals, Vietnam · 1 drug in this class
Janssen Vaccines & Prevention B.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CAIV-T and TIV — Competitive Intelligence Brief. https://druglandscape.com/ci/caiv-t-and-tiv. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab